BioSpace News Archive

Carmot has been acquired by Roche in early 2024, making the company a member of the Roche Group. Carmot Therapeutics is a clinical-stage biotechnology company that is focused on advancing life-changing therapeutics for people with obesity and diabetes.

Global Blood Therapeutics was acquired by Pfizer in August 2022.

At Astellas, we strive to be a cutting-edge, value-driven life science innovator. This means working at the forefront of healthcare change to turn innovative science into the best outcomes for patients. Operating in approximately 70 countries with more than 14,000 employees, we are relentless in our pursuit of scientific progress and in tackling unmet medical needs.

Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease.

Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

Curis is a publicly -traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer.

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates.

We have always walked our own path at Alector. That’s what led us to our bold thinking and fresh, new approach of empowering the body’s immune system to fight disease.

Amunix focuses on immuno-oncology, leveraging our proprietary, clinically validated PRO-XTEN™ technology platform to discover and develop transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer. We aim to expand the therapeutic index of TCEs and cytokines, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose-limiting on-target, off-tumor toxicity.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes.